Takeda’s GI Drug Discovery Unit will work closely with experts from QMUL’s School of Medicine and Dentistry’s neurogastroenterology and immunology groups on several areas of research, including identifying novel therapeutic targets and researching the effect of compounds with novel mechanisms of action. The focus of the research alliance will be GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders.
More articles on GI/endoscopy:
Gotham Medical Associates selects PriorityOne for GI practice IT implementation
Boston Scientific announces 2 product updates
CRE infections at UCLA Medical Center transmitted during ERCP
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.